Edit
Secretome Therapeutics (formerly NeoProgen)
https://secretometx.com/Last activity: 28.05.2026
Probably Closed - Reference to Secretome Therapeutics
University of Maryland, Baltimore (UMB) startup, Secretome Therapeutics (formerly NeoProgen), is developing a novel cell-based therapy for people who experience a heart attack and patients with advanced heart failure. The company’s technology is developed from neonatal Cardiac Progenitor Cells (nCPCs) derived from tissue discarded during lifesaving heart surgery in babies with congenital heart conditions. UMB’s leading pediatric cardiac surgeon, Sunjay Kaushal, MD, PhD, and his lab have published groundbreaking work in preclinical studies that show nCPCs appear to be superior to other cell therapies being pursued by competing academic and commercial groups for functional markers of cardiovascular disease.
Location: United States
Total raised: $30M
Investors 1
| Date | Name | Website |
| - | Maryland M... | momentum.u... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.05.2026 | Series A | $30M | RA Capital... |
Mentions in press and media 5
| Date | Title | Description |
| 01.06.2026 | Secretome Therapeutics Secures $30M, Propels Duchenne Cardiomyopathy Therapy | Secretome Therapeutics closed a $30 million Series A round led by RA Capital. This pivotal funding advances STM-01, an innovative therapy for Duchenne muscular dystrophy-associated cardiomyopathy. The nCPC-derived candidate targets inflamma... |
| 28.05.2026 | Secretome Therapeutics: $30 Million Series A Raised To Advance Duchenne-Associated Cardiomyopathy Therapy | Secretome Therapeutics, a clinical-stage biotechnology company developing therapies derived from neonatal cardiac progenitor cells (nCPC), announced the closing of a $30 million Series A financing led solely by RA Capital Management. The fu... |
| 28.05.2026 | Secretome Therapeutics Raises $30M in Series A Funding | Secretome Therapeutics, a Plano, TX-based clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), raised $30M in Series A funding. The round was led by RA Capital. David Lubner ... |
| 07.09.2022 | University System of Maryland Names Mike Ravenscroft Managing Director of the Maryland Momentum Fund | Baltimore, Md. (Sept. 7, 2022) – The University System of Maryland (USM) has named Mike Ravenscroft as Managing Director of the Maryland Momentum Fund (MMF), a $16 million investment fund that supports early stage companies affiliated with ... |
| 16.10.2019 | NeoProgen Completes $1.5M Seed Financing With $245K Investment From USM Maryland Momentum Fund | University of Maryland, Baltimore (UMB), University of Maryland (UM) Ventures, and TEDCO’s Maryland Venture Fund have also invested in NeoProgen’s innovative cell-based therapy for cardiovascular disease. |